NRIX — Nurix Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.30bn
- $868.56m
- $54.55m
- 56
- 11
- 61
- 37
Annual income statement for Nurix Therapeutics, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 17.8 | 29.8 | 38.6 | 77 | 54.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 82.8 | 148 | 222 | 232 | 268 |
| Operating Profit | -65 | -118 | -184 | -155 | -213 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -63.8 | -117 | -180 | -144 | -193 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -43.2 | -117 | -180 | -144 | -194 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.2 | -117 | -180 | -144 | -194 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.2 | -117 | -180 | -144 | -194 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.11 | -2.73 | -3.71 | -2.65 | -2.88 |